<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557671</url>
  </required_header>
  <id_info>
    <org_study_id>UP2017-Promyce</org_study_id>
    <nct_id>NCT03557671</nct_id>
  </id_info>
  <brief_title>Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins</brief_title>
  <official_title>Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins (TRHF 2017) in Children With Confirmed Immunoglobulin E (IgE) or Non-immunoglobulin E-mediated Cow's Milk Allergy (CMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Statitec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>United Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to show the hypoallergenicity of a new thickened rice based formula&#xD;
      (TRHF) through a double blind placebo controlled food challenge (DBPCFC), as recommended by&#xD;
      the American Academy of Pediatrics, in subjects with IgE-mediated CMA and in subjects with&#xD;
      non-IgE-mediated CMA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is made of 2 different steps : 1st step is a double blind randomised food challenge&#xD;
      where the new formula is compared to a placebo.&#xD;
&#xD;
      The second part of the trial consists in an open phase during which all infants will be fed&#xD;
      with the study formula.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 23, 2018</start_date>
  <completion_date type="Actual">September 21, 2020</completion_date>
  <primary_completion_date type="Actual">September 21, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hypoallergenicity</measure>
    <time_frame>7 days</time_frame>
    <description>the percentage of children tolerating the formula during the double blind placebo controlled food challenge (TRHF 2017 vs. placebo formula).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regurgitations</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>assessed through Vandenplas score ranging from 0 (=less than 2 regurgitation episodes / day) to 6 (=Regurgitation of the complete volume after each feeding)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>(on a 4 level scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal pain</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>(severity on a 4 level scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bloating and gas</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>(severity on a 4 level scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>assessed through Bristol Stools Form Scale from Type A ( Separate hard lumps, like nuts (hard to pass)) to Type G (Watery, not solid pieces - entirely liquid )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>(number of stool per day or per week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood in stools</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>(presence/absence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleeping time over 24h satisfaction</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>(presence/absence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unexplained crying</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>(yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory symptoms</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>(severity on a 4 level scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urticaria</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>(presence/absence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angioedema</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>(presence/absence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eczema</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>severity assessed through SCORAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>expressed in kg and in z scores according to the World Health Organization (WHO) Child Growth Standards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>expressed in cm and in z scores according to the WHO Child Growth Standards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>expressed in value and z scores according to the WHO Child Growth Standards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head circumference</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>expressed in cm and in z scores according to the WHO Child Growth Standards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment emergent Adverse Events</measure>
    <time_frame>1, 2, 3, 4, 5 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Cow Milk Allergy</condition>
  <arm_group>
    <arm_group_label>TRHF - Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subjects will receive both TRHF and placebo formula during the 1st part of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - TRHF</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subjects will receive both TRHF and placebo formula during the 1st part of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>rice formula</intervention_name>
    <description>new rice based thickened formula</description>
    <arm_group_label>Placebo - TRHF</arm_group_label>
    <arm_group_label>TRHF - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>formula previously tolerated by the subject - only for the 1st part of the study</description>
    <arm_group_label>Placebo - TRHF</arm_group_label>
    <arm_group_label>TRHF - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  with suspected CMA or with a CMA diagnosed by a DBPCFC performed in the last 2 months&#xD;
             prior to inclusion&#xD;
&#xD;
          -  free of clinical allergic symptoms for at least one week (i.e. successfully fed an&#xD;
             elimination diet);&#xD;
&#xD;
          -  whose parents signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  mainly breast fed, drinking less than 250ml of formula/day, presenting any situation,&#xD;
             which, according to the investigator, may interfere with the study participation or&#xD;
             lead to a particular risk for the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Berni Canani</last_name>
    <role>Study Director</role>
    <affiliation>University Federico II</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHR Namur</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint Vincent de Paul - GHICL</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Naples Federico II</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Milk Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

